ALFASIGMA INNOVATIVE DRUGS RDI

Promoteur – Intermédiaire Financier

ALFASIGMA SPA

Lieu

• Italie

Description

The project will finance Alfasigma's R&D investments to be made in the period 2019-2022. In particular, financing will cover the promoter's research activities (clinical and regulatory development) for the development of innovative drugs in the areas of gastroenterology, vascular medicine and rheumatology.

Objectifs

By co-investing in this project, the EIB contributes to making medical treatments for what the healthcare system considers high priority diseases, whilst also fostering the generation of European scientific knowledge and acumen.

Secteur(s)

• Services - Activités spécialisées, scientifiques et techniques

Montant BEI envisagé (montant approximatif)

EUR 100 million

Coût total (montant approximatif)

EUR 251 million

Aspects environnementaux

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Passation des marchés

Alfasigma is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Statut

Signé - 13/09/2019